Analysts See $0.51 EPS for Inogen, Inc. (INGN)

October 13, 2018 - By Dolores Ford

Inogen, Inc. (NASDAQ:INGN) LogoInvestors sentiment decreased to 1.04 in 2018 Q2. Its down 0.06, from 1.1 in 2018Q1. It turned negative, as 23 investors sold Inogen, Inc. shares while 76 reduced holdings. 42 funds opened positions while 61 raised stakes. 19.88 million shares or 0.20% more from 19.84 million shares in 2018Q1 were reported.
Foundry Prtnrs Ltd Com stated it has 24,259 shares or 0.18% of all its holdings. 4,611 were accumulated by Yorktown Management &. Johnson Investment Counsel Incorporated reported 0.15% of its portfolio in Inogen, Inc. (NASDAQ:INGN). Pdts Prtn Lc holds 0.38% or 53,600 shares in its portfolio. Proshare Advsr Ltd Liability Co, Maryland-based fund reported 2,886 shares. Public Employees Retirement Sys Of Ohio holds 0.02% of its portfolio in Inogen, Inc. (NASDAQ:INGN) for 22,765 shares. Principal Gp reported 145,722 shares or 0.02% of all its holdings. Cornerstone Advisors holds 0% of its portfolio in Inogen, Inc. (NASDAQ:INGN) for 5 shares. Lord Abbett Limited Liability has 155,108 shares for 0.08% of their portfolio. Ameritas Inv reported 1,440 shares. The North Carolina-based Sterling Cap Mgmt Ltd Com has invested 0.04% in Inogen, Inc. (NASDAQ:INGN). Fmr Ltd Limited Liability Company invested in 34,300 shares or 0% of the stock. Lpl Fincl Limited Liability Com accumulated 1,497 shares. Macquarie Grp Inc invested in 0.01% or 19,428 shares. Martingale Asset Management Ltd Partnership owns 2,801 shares.

Analysts expect Inogen, Inc. (NASDAQ:INGN) to report $0.51 EPS on November, 6.They anticipate $0.18 EPS change or 54.55 % from last quarter’s $0.33 EPS. INGN’s profit would be $10.89M giving it 98.74 P/E if the $0.51 EPS is correct. After having $0.65 EPS previously, Inogen, Inc.’s analysts see -21.54 % EPS growth. The stock increased 1.47% or $2.92 during the last trading session, reaching $201.42. About 457,735 shares traded or 46.53% up from the average. Inogen, Inc. (NASDAQ:INGN) has risen 162.95% since October 14, 2017 and is uptrending. It has outperformed by 147.33% the S&P500.

Inogen, Inc. (NASDAQ:INGN) Ratings Coverage

Among 5 analysts covering Inogen (NASDAQ:INGN), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Inogen had 7 analyst reports since May 1, 2018 according to SRatingsIntel. Needham downgraded Inogen, Inc. (NASDAQ:INGN) on Monday, September 10 to “Buy” rating. Needham maintained the stock with “Buy” rating in Tuesday, May 1 report. J.P. Morgan maintained it with “Buy” rating and $18000 target in Tuesday, May 1 report. Stifel Nicolaus maintained Inogen, Inc. (NASDAQ:INGN) on Wednesday, August 22 with “Buy” rating. JP Morgan maintained Inogen, Inc. (NASDAQ:INGN) on Tuesday, May 1 with “Overweight” rating. Needham maintained the shares of INGN in report on Monday, June 11 with “Buy” rating.

Inogen, Inc., a medical technology company, primarily develops, makes, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company has market cap of $4.30 billion. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It has a 139.97 P/E ratio. It offers Inogen One systems, which are portable devices that concentrate the air around the patients to provide a single source of supplemental oxygen; and Inogen At Home stationary oxygen concentrators, as well as related accessories.

Another recent and important Inogen, Inc. (NASDAQ:INGN) news was published by which published an article titled: “Vanda Pharma gains, Aceto drops amid S&P index changes” on September 25, 2018.

Inogen, Inc. (NASDAQ:INGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: